Sanofi dengue vaccine meets Phase III endpoint

Sanofi (Euronext:SAN; NYSE:SNY) said its dengue vaccine met the primary endpoint vs. placebo in a Phase III trial. The subcutaneous vaccine reduced symptomatic, virologically confirmed dengue fever cases by 60.8% vs. placebo and showed efficacy against all four dengue serotypes.

The double-blind Latin American trial enrolled 20,875 healthy adolescents ages 9-16. Positive results from a Phase III trial of the vaccine in 10,275 children in Asia were announced in April. The vaccine is a chimeric tetravalent dengue vaccine consisting of live attenuated yellow fever virus 17D strain with structural genes replaced with the corresponding dengue structural genes (see BioCentury Extra, April 28). ...